| MHCII is required for α-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration AS Harms, S Cao, AL Rowse, AD Thome, X Li, LR Mangieri, RQ Cron, ... Journal of Neuroscience 33 (23), 9592-9600, 2013 | 389 | 2013 |
| microRNA-155 regulates alpha-synuclein-induced inflammatory responses in models of Parkinson disease AD Thome, AS Harms, LA Volpicelli-Daley, DG Standaert Journal of Neuroscience 36 (8), 2383-2390, 2016 | 252 | 2016 |
| Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease AS Harms, AD Thome, Z Yan, AM Schonhoff, GP Williams, X Li, Y Liu, ... Experimental neurology 300, 179-187, 2018 | 186 | 2018 |
| α-Synuclein fibrils recruit peripheral immune cells in the rat brain prior to neurodegeneration AS Harms, V Delic, AD Thome, N Bryant, Z Liu, S Chandra, ... Acta neuropathologica communications 5, 1-16, 2017 | 174 | 2017 |
| Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson’s disease GP Williams, AM Schonhoff, A Jurkuvenaite, AD Thome, DG Standaert, ... Journal of neuroinflammation 15, 1-14, 2018 | 71 | 2018 |
| Fractalkine signaling regulates the inflammatory response in an α-synuclein model of Parkinson disease AD Thome, DG Standaert, AS Harms PloS one 10 (10), e0140566, 2015 | 67 | 2015 |
| Restoring regulatory T-cell dysfunction in Alzheimer’s disease through ex vivo expansion A Faridar, AD Thome, W Zhao, JR Thonhoff, DR Beers, B Pascual, ... Brain communications 2 (2), fcaa112, 2020 | 57 | 2020 |
| Functional alterations of myeloid cells during the course of Alzheimer’s disease AD Thome, A Faridar, DR Beers, JR Thonhoff, W Zhao, S Wen, B Pascual, ... Molecular Neurodegeneration 13, 1-11, 2018 | 53 | 2018 |
| Elevated acute phase proteins reflect peripheral inflammation and disease severity in patients with amyotrophic lateral sclerosis DR Beers, W Zhao, DW Neal, JR Thonhoff, AD Thome, A Faridar, S Wen, ... Scientific reports 10 (1), 15295, 2020 | 43 | 2020 |
| Ex vivo expansion of dysfunctional regulatory T lymphocytes restores suppressive function in Parkinson’s disease AD Thome, F Atassi, J Wang, A Faridar, W Zhao, JR Thonhoff, DR Beers, ... npj Parkinson's Disease 7 (1), 41, 2021 | 36 | 2021 |
| The metabotropic glutamate receptor 4 positive allosteric modulator ADX88178 inhibits inflammatory responses in primary microglia R Ponnazhagan, AS Harms, AD Thome, A Jurkuvenaite, R Gogliotti, ... Journal of neuroimmune pharmacology 11 (2), 231-237, 2016 | 32 | 2016 |
| Immunosuppressive functions of M2 macrophages derived from iPSCs of patients with ALS and healthy controls W Zhao, DR Beers, JR Thonhoff, AD Thome, A Faridar, J Wang, S Wen, ... Iscience 23 (6), 2020 | 25 | 2020 |
| A partial MECP2 duplication in a mildly affected adult male: a putative role for the 3' untranslated region in the MECP2 duplication phenotype NA Hanchard, CMB Carvalho, P Bader, A Thome, L Omo-Griffith, ... BMC Medical Genetics 13, 1-9, 2012 | 19 | 2012 |
| Ex vivo expanded human regulatory T cells modify neuroinflammation in a preclinical model of Alzheimer’s disease A Faridar, M Vasquez, AD Thome, Z Yin, H Xuan, JH Wang, S Wen, X Li, ... Acta Neuropathologica Communications 10 (1), 144, 2022 | 17 | 2022 |
| Extracellular Vesicles Derived From Ex Vivo Expanded Regulatory T Cells Modulate In Vitro and In Vivo Inflammation AD Thome, JR Thonhoff, W Zhao, A Faridar, J Wang, DR Beers, SH Appel Frontiers in Immunology 13, 875825, 2022 | 16 | 2022 |
| Tregs attenuate peripheral oxidative stress and acute phase proteins in ALS DR Beers, JR Thonhoff, A Faridar, AD Thome, W Zhao, S Wen, SH Appel Annals of neurology 92 (2), 195-200, 2022 | 15 | 2022 |
| Combined regulatory T-lymphocyte and IL-2 treatment is safe, tolerable, and biologically active for 1 year in persons with amyotrophic lateral sclerosis JR Thonhoff, JD Berry, EA Macklin, DR Beers, PA Mendoza, W Zhao, ... Neurology: Neuroimmunology & Neuroinflammation 9 (6), e200019, 2022 | 14 | 2022 |
| Serum programmed cell death proteins in amyotrophic lateral sclerosis DR Beers, W Zhao, JR Thonhoff, A Faridar, AD Thome, S Wen, J Wang, ... Brain, Behavior, & Immunity-Health 12, 100209, 2021 | 5 | 2021 |
| A phase 1 open-label pilot study of low-dose interleukine-2 immunotherapy in patients with Alzheimer’s disease A Faridar, AM Eid, AD Thome, W Zhao, DR Beers, MB Pascual, ... Translational Neurodegeneration 12 (1), 54, 2023 | 1 | 2023 |
| A Phase 1 Clinical Trial of IL‐2 in Patients with Alzheimer’s Disease: A Regulatory T Cell Expansion Strategy Targeting Inflammation A Faridar, AM Eid, AD Thome, W Zhao, D Beers, B Pascual, MO Nakawah, ... Alzheimer's & Dementia 19, e073878, 2023 | | 2023 |
